XKRX214150
Market cap2.20bUSD
Dec 24, Last price
49,500.00KRW
1D
1.33%
1Q
-7.48%
IPO
972.59%
Name
Classys Inc
Chart & Performance
Profile
CLASSYS Inc. provides medical aesthetics devices worldwide. Its products include SCIZER for non-invasive subcutaneous fat reduction; ULTRAFORMER MPT, a solution for eyebrow lifting by coagulating skin tissue with a focused ultrasound stimulation system; ULTRAFORMER III, a high-intensity focused ultrasound surgical device used for tissue coagulation in eyelid lifting for skin tightening and improving subcutaneous tissue elasticity in the face (cheeks), abdomen, and thighs, as well as for addressing crow's feet, laugh lines, and neck wrinkles; INTRASURE, an aesthetics and healthcare multi-platform solution; FORSHAPE, an RF treatment system to increase metabolism, blood circulation, and tissue recovery; and VOLNEWMER, a monopolar radiofrequency therapeutic equipment used to coagulate skin tissue as a general electrosurgical instrument. It also provides CLATUU Alpha, a medical device that gradually reduces subcutaneous fat layers, particularly in areas with excessive fat accumulation, using low-temperature energy and negative pressure; Ulfit, a medical device used to improve skin elasticity and subcutaneous tissue in the abdomen and thighs by delivering HIFU energy; Refit, a medical device that uses RF and negative pressure to increase tissue temperature and blood flow, relieving pain in the treated area; AQUAPURE is the combination of four handpieces are respectively applied for acne suction, muscle pain relief, and other pain relief; and AQUAPURE II, a multi-functional facial and body care device. The company offers its products under the Classys, Cluederm, and the SKEDERM brands. It serves clinics, hospitals, and beauty salons. The company was incorporated in 2007 and is headquartered in Seoul, South Korea.
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
Income | |||||
Revenues | 180,122,798 27.02% | 141,803,242 40.96% | 100,596,936 31.57% | ||
Cost of revenue | 74,054,264 | 58,265,403 | 36,718,742 | ||
Unusual Expense (Income) | |||||
NOPBT | 106,068,534 | 83,537,840 | 63,878,194 | ||
NOPBT Margin | 58.89% | 58.91% | 63.50% | ||
Operating Taxes | 19,616,641 | 21,379,789 | 11,819,912 | ||
Tax Rate | 18.49% | 25.59% | 18.50% | ||
NOPAT | 86,451,893 | 62,158,050 | 52,058,282 | ||
Net income | 74,225,203 -1.53% | 75,378,647 72.08% | 43,804,676 14.78% | ||
Dividends | (7,471,452) | (4,271,313) | (3,882,550) | ||
Dividend yield | 0.31% | 0.36% | 0.32% | ||
Proceeds from repurchase of equity | (14,578,009) | (5,313,131) | 13,999 | ||
BB yield | 0.60% | 0.45% | 0.00% | ||
Debt | |||||
Debt current | 3,139,369 | 2,957,303 | 514,155 | ||
Long-term debt | 63,716,796 | 66,039,931 | 36,097,055 | ||
Deferred revenue | 207,422 | 690,712 | 178,000 | ||
Other long-term liabilities | 10 | (170) | |||
Net debt | 44,312,305 | 41,623,090 | (8,368,691) | ||
Cash flow | |||||
Cash from operating activities | 64,631,972 | 54,754,505 | 36,367,042 | ||
CAPEX | (6,112,522) | (27,998,696) | (33,037,660) | ||
Cash from investing activities | (48,157,758) | (91,994,853) | (92,466,135) | ||
Cash from financing activities | (25,643,962) | 21,055,239 | 30,719,729 | ||
FCF | 20,162,199 | 45,123,787 | 13,665,752 | ||
Balance | |||||
Cash | 137,837,865 | 113,223,567 | 48,771,336 | ||
Long term investments | (115,294,004) | (85,849,422) | (3,791,435) | ||
Excess cash | 13,537,721 | 20,283,982 | 39,950,054 | ||
Stockholders' equity | 279,270,730 | 210,746,078 | 139,622,327 | ||
Invested Capital | 335,798,284 | 258,725,300 | 153,812,329 | ||
ROIC | 29.08% | 30.13% | 49.31% | ||
ROCE | 30.36% | 29.94% | 32.90% | ||
EV | |||||
Common stock shares outstanding | 64,405 | 64,703 | 64,800 | ||
Price | 37,750.00 105.16% | 18,400.00 -2.13% | 18,800.00 22.08% | ||
Market cap | 2,431,290,713 104.22% | 1,190,529,698 -2.27% | 1,218,236,560 22.09% | ||
EV | 2,475,603,018 | 1,232,152,788 | 1,209,867,869 | ||
EBITDA | 110,346,173 | 87,437,535 | 66,401,209 | ||
EV/EBITDA | 22.43 | 14.09 | 18.22 | ||
Interest | 1,958,684 | 2,609,848 | 93,054 | ||
Interest/NOPBT | 1.85% | 3.12% | 0.15% |